Empagliflozin vs statins for fatty liver disease
Treatments studied
Part of Digestive system clinical trials.
This study compares two medicines, empagliflozin and statins, to see which works better for people with fatty liver disease and related conditions like diabetes, obesity, and high cholesterol.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You are obese
- You have high cholesterol (hyperlipidemia)
- You have diabetes
- You are diagnosed with fatty liver disease (NAFLD) or NASH
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two diabetes pills (pioglitazone and empagliflozin) to see if they can reduce liver fat in people with type 2 diabetes and fatty liver disease. It may help if your diabetes is not well controlled and you have a fatty liver confirmed by a special ultrasound scan.
This trial tests a diabetes drug called empagliflozin to see if it can reduce fat and inflammation in the liver in people with a specific type of fatty liver disease called NASH. It may help if you have NASH and either have type 2 diabetes or don't have it.
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
This Phase 2 study tests whether low-dose pioglitazone can improve NASH, a type of fatty liver disease, in adults who also have type 2 diabetes. You may be able to join if your diabetes medicines and lab tests meet specific safety and stability requirements.
This study tests a medication called empagliflozin (a type of SGLT2 inhibitor) to see if it can help treat fatty liver disease in teenagers and young adults. It may improve liver health and help with weight management.
This study tests whether SGLT2 inhibitors, a type of diabetes medication, can help reduce fat buildup in the liver (NAFLD) for people with type 2 diabetes who also have moderate kidney problems (stage 3 or 4 CKD). It may offer a new way to treat both conditions together.
Hear when a new Non-alcoholic Fatty Liver Disease NAFLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.